Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicergoline Bioequivalence Study in Healthy Chinese Participants
NCT04176367Phase 1Completed
- Sponsor
- Viatris
- Start
- Dec 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nicergoline in Dementia and vascular dementia (2 arms), sponsored by Viatris. Primary endpoints: Area Under the Curve from Time 0 to Infinity at Day 11, Area Under the Curve from Time 0 to Last Quantifiable Concentration at Day 11 and 1 more. Started Dec 2019; status: completed.
02
Drugs
nicergoline
03
Conditions
Dementiavascular dementia
Beyond the preview
Go deeper on NCT04176367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04176367.